# Combined effect of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer

## TL;DR

Combining Tislelizumab with chemotherapy improves tumor control and survival in small cell lung cancer patients compared to chemotherapy alone.

## Contribution

Demonstrates that combining Tislelizumab with chemotherapy improves tumor marker levels and immune function in SCLC patients.

## Key findings

- The Combined group had a higher tumor control rate than the Chemotherapy group.
- Combined treatment led to lower levels of CEA, NSE, and CYFRA21-1 tumor markers.
- Combined treatment improved CD3+ and CD4+ T cell levels and reduced disease recurrence.

## Abstract

Exploring the effect of the combined regimen of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer (SCLC).

This retrospective analysis included data of 80 SCLC patients treated in Jiangxi Cancer Hospital from April 2021 to April 2023. Forty patients who were treated with a combination of chemotherapy and Tislelizumab (the Combined group) were matched in a 1:1 ratio with a cohort receiving chemotherapy alone (the Chemotherapy group). Levels of tumor markers and T cell subsets in both groups were compared before and after treatment. After six months of follow-up, the early disease recurrence rate and survival rate of the two groups were compared.

The tumor control rate of the Combined group was higher than that of the Chemotherapy group (P<0.05). After treatment, the serum levels of carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin-19-fragment (CYFRA21-1) in both groups decreased compared to before treatment and were lower in the Combined group compared to the Chemotherapy group (P<0.05). Combined treatment was associated with higher levels of CD3+, CD4+, and CD4+/CD8+ (P<0.05). The disease recurrence rate was lower, and the survival rate was higher in the patients who received the combined treatment than those treated by the chemotherapy alone(P<0.05).

Adopting the conventional combination of Tislelizumab and chemotherapy to treat SCLC can downregulate tumor marker levels, improve immune function, enhance treatment efficacy, and ensure disease prognosis. Longer follow-up is needed to confirm long-term prognostic benefits.